Evidence map›Paper›PMID 33144487›Full record

ArticleIn vivo (Athens, Greece)

A Novel Systemic Inflammatory Score Combined With Immunoinflammatory Markers Accurately Reflects Prognosis in Patients With Esophageal Cancer.

Takafumi Suzuki, Yusuke Ishibashi, Hironori Tsujimoto, Shinsuke Nomura, Keita Kouzu, Yujiro Itazaki, Takao Sugihara, Manabu Harada, Nozomi Ito, Hidekazu Sugasawa and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in In vivo (Athens, Greece). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Article
  7. Targeting the Microenvironment in Esophageal Cancer.Frontiers in cell and developmental biology · 2021
    Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Takafumi SuzukiDepartment of Surgery, National Defense Medical College, Saitama, Japan.
Yusuke IshibashiDepartment of Surgery, National Defense Medical College, Saitama, Japan yuusuke0102_0908@yahoo.co.jp.
Hironori TsujimotoDepartment of Surgery, National Defense Medical College, Saitama, Japan.
Shinsuke NomuraDepartment of Surgery, National Defense Medical College, Saitama, Japan.
Keita KouzuDepartment of Surgery, National Defense Medical College, Saitama, Japan.
Yujiro ItazakiDepartment of Surgery, National Defense Medical College, Saitama, Japan.
Takao SugiharaDepartment of Surgery, National Defense Medical College, Saitama, Japan.
Manabu HaradaDepartment of Surgery, National Defense Medical College, Saitama, Japan.
Nozomi ItoDepartment of Surgery, National Defense Medical College, Saitama, Japan.
Hidekazu SugasawaDepartment of Surgery, National Defense Medical College, Saitama, Japan.
Yoji KishiDepartment of Surgery, National Defense Medical College, Saitama, Japan.
Hideki UenoDepartment of Surgery, National Defense Medical College, Saitama, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimTo establish a novel systemic inflammatory score (SIS) combined with neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and C-reactive protein/albumin ratio (CAR) and to validate its prognostic value and relation with serum cytokine levels in patients who underwent esophagectomy for esophageal cancer (EC). PATIENTS AND

methodsPreoperative NLR, PLR, and CAR were evaluated in 102 patients undergoing esophageal resection for EC from 2009 to 2014. Receiver operating characteristic (ROC) curves censored for 5-year survival were plotted to determine the cutoff values of each measure. Each measure was scored 1 if it was above the cutoff value (NLR >3.12, PLR >230, and CAR >0.085) and scored 0 if it was below that. The SIS was defined as the sum of these values and was divided into the two groups: High SIS (SIS=2-3) and low SIS (SIS=0-1). Univariate and multivariate analyses were used to determine the prognostic significance. The area under the ROCs (AUROC) was compared to verify the discriminative power of survival prediction. In addition, we analyzed the relationship between SIS and perioperative serum interleukin (IL)-6 and IL-10 levels.

resultsIn the clinicopathological findings, only tumor depth was significantly related to SIS (p=0.004). At 0.732, the AUROC of SIS was the highest (NLR=0.618, PLR=0.545), and CAR=0.712). The high-SIS group had a significantly poorer prognosis than the low-SIS group (p=0.011). SIS was identified as an independent prognostic factor in the multivariate analysis (hazard ratio=1.96, 95% confidence intervaI=1.11-3.41, p=0.020). The preoperative serum interleukin-6 level was significantly low (p=0.046) and postoperative serum interleukin-10 level was significantly high in the high-SIS group (p=0.047).

conclusionSIS was a superior predictor of prognosis compared with existing immunoinflammatory markers and closely reflected the fluctuation of peripheral inflammatory cytokines in patients with EC.

Indexed as

Carcinoma, Squamous CellEsophageal NeoplasmsEsophagectomyHumansLymphocytesPrognosisRetrospective StudiesC-reactive protein/albumin ratioEsophageal cancerneutrophil-lymphocyte ratioplatelet-lymphocyte ratioprognosis

Identifiers

PMID33144487
PMCPMC7811597

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.